Amgen (AMGN)

$298.62 0.12 (0.04%)

16:00 EDT AMGN Stock Quote Delayed 30 Minutes

3 Stocks to Buy as Ozempic Surges in Popularity

By Joey Frenette, InvestorPlace Contributor Jun 13, 2024

Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.

Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now

7 Reliable Blue-Chip Stocks That Cannot Miss

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 1.71M

Day's Range $295.90 - $299.74

52-Week Range $218.44 - $329.72

Dividend & Yield $8.52 (2.85%)

AMGN Stock Predictions, Articles, and Amgen News

The 3 Best Dow Stocks to Buy in May 2024

By Larry Ramer, InvestorPlace Contributor May 13, 2024

The Dow Jones Industrial Average has been on a hot streak this month. Here are the three best Dow stocks to buy.

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

By Alex Sirois, InvestorPlace Contributor May 9, 2024

The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.

Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street

By Tezcan Gecgil, InvestorPlace Contributor May 9, 2024

Discover the reasons behind three stocks attracting investor attention as they stand on the precipice of future growth.

3 Tried and True Dividend Stocks to Buy for Your Portfolio

By Prakash Kolli May 7, 2024

These dividend stocks to buy represent time-tested companies with significant growth potential. Dive in now to strengthen your portfolio.

AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?

By Larry Ramer, InvestorPlace Contributor May 3, 2024

Amgen (AMGN) stock is soaring after the company's CEO said he was "very encouraged" by interim data for Amgen's new weight-loss drug.

AMGN Stock Earnings: Amgen Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 2, 2024

AMGN stock results show that Amgen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can

By Yiannis Zourmpanos, InvestorPlace Contributor May 1, 2024

Uncover the vulnerabilities of these Dow stocks to sell, with potential declines due to cash flow issues, pricing pressures and flat sales.

Spring Awakening: 3 Dow Stocks Emerging from Hibernation

By Ian Cooper, InvestorPlace Contributor Apr 25, 2024

The last time we spoke about the top blue-chip stocks to buy on dips, we highlighted opportunity in the 2024 Dogs of the Dow.

The Dividend Goldmine: 3 Shining Stocks With Growing Payouts

By Yiannis Zourmpanos, InvestorPlace Contributor Apr 19, 2024

Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

By Chandler Capital, InvestorPlace Contributor Apr 17, 2024

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble

By Viktor Zarev, InvestorPlace Contributor Apr 17, 2024

Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.

The 3 Best Biotech Stocks to Buy Now: Q2 Edition

By Ian Cooper, InvestorPlace Contributor Apr 16, 2024

Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.

3 Stocks to Buy Low Today With High Hopes for Tomorrow

By Stavros Tousios, InvestorPlace Contributor Apr 15, 2024

Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns.

3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April

By Chris MacDonald, InvestorPlace Contributor Apr 9, 2024

These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.

The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024

By Michael Que, InvestorPlace Contributor Apr 7, 2024

Our economy is on the up and up, and investing is a must,. Let's review the most undervalued S&P 500 stocks to buy in April.

3 Biotech Stocks to Buy on the Dip: March 2024

By Ian Cooper, InvestorPlace Contributor Mar 27, 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

Buffett’s Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating

By Rich Duprey, InvestorPlace Contributor Mar 25, 2024

Warren Buffett stocks and Berkshire Hathaway's portfolio of companies are hidden investment vehicles hiding in plain sight.

Hot Stocks: The 3 Best Opportunities for Investing in Biotech

By Chandler Capital, InvestorPlace Contributor Mar 21, 2024

Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now.

Hot Stocks: The 3 Best Opportunities for Investing in the Dow

By Josh Enomoto, InvestorPlace Contributor Mar 20, 2024

While investing in Dow stocks – that is, the 30 companies making up the Dow Jones Industrial Average – might seem incredibly boring, investors shouldn’t…

Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks

By Josh Enomoto, InvestorPlace Contributor Mar 10, 2024

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last…

Amgen (AMGN)

3 Stocks to Buy as Ozempic Surges in Popularity

Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now

7 Reliable Blue-Chip Stocks That Cannot Miss

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Amgen (AMGN)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

AMGN Stock Predictions, Articles, and Amgen News

Subscriber Sign in